Business Context and Reporting Period
Company: Bristol-Myers Squibb Company
Filing Type: Form 8-K (Current Report)
Date of Report: May 11, 2005
Event: Completion of the sale of the Oncology Therapeutics Network (OTN) distribution business to One Equity Partners LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification of a corporate transaction rather than a financial statement.
Material Changes
- Asset Divestiture: Bristol-Myers Squibb completed the sale of its OTN distribution business.
- Counterparty: The business was sold to One Equity Partners LLC.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, specific risks, or contingencies related to this transaction. The report references an attached press release (Exhibit 99.1) for further details, but the content of that press release is not included in the provided text.
Investor Verification Checklist
- Verify the financial terms of the OTN sale (e.g., purchase price, consideration structure) in the attached press release or subsequent filings.
- Confirm the impact of the divestiture on future revenue streams and operating expenses.
- Review the press release (Exhibit 99.1) for any strategic rationale or future plans regarding the oncology distribution segment.